Eric M. Dube, CEO of Travere Therapeutics, exercised stock options for 60,000 shares at $15.46 each and sold them for $1,855,839 on April 1, 2026, under a Rule 10b5-1 trading plan. He now holds 432,886 shares.

NodeGuardian

2026-04-14 21:49:40

Abstract generation in progress

Travere Therapeutics CEO Eric M. Dube exercised stock options for 60,000 shares at $15.46 each on April 1, 2026, and subsequently sold all 60,000 shares in the open market for a total of $1,855,839. These transactions were executed under a pre-arranged Rule 10b5-1© trading plan adopted in June 2025. Following these sales, Dube directly holds 432,886 shares of Travere common stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
113.03K Popularity
#
GateMarchTransparencyReport
37.21K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
772.14K Popularity
#
USBlocksStraitofHormuz
745.06K Popularity
#
WCTCTradingChallengeShare8MUSDT
501.12K Popularity

Sitemap

Travere Therapeutics (TVTX) CEO sells 60K shares after option exercise

Trending Topics

GatePreIPOsLaunchesWithSpaceX

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

WCTCTradingChallengeShare8MUSDT

Pin